Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: The present invention pertains to: an antibody that specifically recognizes cancer stem cells; a pharmaceutical composition containing the antibody, in particular a pharmaceutical composition for treating cancer; the utilization of these; a method for treating cancer, the method targeting cancer stem cells; etc. The above problem was solved by providing an antibody that recognizes a complex of a cancer stem cell antigen peptide and an MHC, and a pharmaceutical composition containing the antibody as an active component.

Abstract: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.

Abstract: The object of the present invention is to provide a detecting agent for specifically detecting a tumor cell, a tumor antigen peptide-specifically presented on a tumor cell, a pharmaceutical composition useful for the prevention and/or treatment of cancer, the pharmaceutical composition containing the tumor antigen peptide as an active ingredient, etc. The above object has been achieved by a tumor antigen peptide or its motif-substituted product, the tumor antigen peptide comprising 8 to 14 consecutive amino acids in an amino acid sequence of a protein encoded by a gene selected from the group consisting of PVT1, SUV39H2, ZNF724P, SNRNP40, and DYRK4, the tumor antigen peptide having an HLA binding ability.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.

Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting a cancer stem cell; a tumor antigen peptide specifically presented by cancer stem cells; a medicinal composition useful in preventing and/or treating cancer, said medicinal composition comprising the aforementioned tumor antigen peptide as an active ingredient; a method for screening the tumor antigen peptide; etc. To achieve the above-mentioned purpose, provided are: peptides represented by YO-XO-ZO; a polyepitope peptide consisting of a plurality of epitope peptides connected together, said polyepitope peptide containing at least one of the above-mentioned peptides as one of the epitope peptides; a polynucleotide encoding the aforementioned peptides and/or polyepitope peptide; a medicinal composition comprising the same as an active ingredient; a prophylactic and/or therapeutic agent for cancer characterized by inducing CTL; etc.

Abstract: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: The purpose of the present invention is to provide: a detection agent for specifically detecting cancer stem cells; a tumor antigen peptide specifically exhibited by cancer stem cells; a pharmaceutical composition for the prevention and/or treatment of cancer, containing same as an effective component thereof; and a method for screening said tumor antigen peptide. A peptide indicated by YO—XO—ZO, a polyepitope peptide including at least one said peptide as an epitope peptide and having a plurality of epitope peptides joined therein, a polynucleotide that codes at least either the peptide or the polyepitope peptide, a pharmaceutical composition containing these as an effective component thereof, and a cancer prevention and/or treatment agent characterized by inducing CTLs.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: Provided is a tumor antigen peptide and the like that is useful in the prevention and/or treatment of cancer. The present invention pertains to: a peptide comprising the amino acid sequence of sequence number 3, sequence number 4, sequence number 5, sequence number 6, or sequence number 11; a polyepitope peptide resulting from joining a plurality of epitope peptides and containing at least one of the aforementioned peptides as one epitope peptide; a polynucleotide coding for at least one of the polyepitope peptides or the peptides; a pharmaceutical composition containing the above as active ingredients; a cancer prevention and/or treatment agent characterized by inducing CTLs; and the like.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Abstract: [Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like. [Technical Solution] The present invention comprises the substance having an inhibitory activity of histone deacetylase (HDAC) as an active component.

Abstract: The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.

Abstract: The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.